Cargando…
Pneumocystis jirovecii Pneumonia during Brentuximab Vedotin Therapy: A Case Report and Literature Review
Brentuximab vedotin (BV), an antibody drug conjugate against CD30, has been increasingly used in clinical practice, and the less common adverse events associated to the drug are not well described. Also, opportunistic infections have been reported, and data on immune reconstitution after use of BV a...
Autores principales: | Ferreira, Aliana Meneses, Ramos, Jessica Fernandes, Fatobene, Giancarlo, Rocha, Vanderson |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458937/ https://www.ncbi.nlm.nih.gov/pubmed/31049233 http://dx.doi.org/10.1155/2019/8982937 |
Ejemplares similares
-
Brentuximab Vedotin
Publicado: (2012) -
Pneumocystis jirovecii pneumonia following corticosteroid therapy
por: Garça, Magda, et al.
Publicado: (2023) -
Brentuximab vedotin induced uveitis
por: Therssen, Stijn, et al.
Publicado: (2022) -
Pneumocystis jirovecii pneumonia in developing countries
por: De Armas Rodríguez, Y., et al.
Publicado: (2011) -
Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013)